Literature DB >> 15475413

Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta.

Daisuke Kobayashi1, Ichiro Ieiri, Takeshi Hirota, Hiroshi Takane, Shinji Maegawa, Junzo Kigawa, Hiroshi Suzuki, Eiji Nanba, Mitsuo Oshimura, Naoki Terakawa, Kenji Otsubo, Kazunori Mine, Yuichi Sugiyama.   

Abstract

The aim of the present study was to assess the contribution of polymorphisms in the breast cancer resistance protein/ATP-binding cassette transporter G2 (BCRP/ABCG2) gene to the placental expression from a new perspective, allelic imbalance. Polymorphisms were screened by polymerase chain reaction (PCR)-single-strand conformation polymorphism analysis followed by sequencing with DNA extracted from 100 placentas. To examine whether polymorphisms of the BCRP gene correlate with the placental BCRP expression, we determined mRNA and protein levels by quantitative real-time PCR and Western blotting, respectively. In placentas, G34A (Val(12)Met) and C421A (Gln(141)Lys) were frequently observed (18-36%), but C376T, which creates a stop codon (Gln(126) stop codon), was found with an allelic frequency of 1%. The mean of the BCRP protein level was significantly lower (p < 0.05) in homozygotes for the A421 allele than in those for the C421 allele, and heterozygotes had an intermediate value. To evaluate whether the C421A polymorphism acts as a cis-element in BCRP transcription, allelic imbalance was determined using informative lymphoblasts and 56 samples of placental cDNA. In most of the placental samples we tested, the difference in expression levels between the two alleles was small, and only two samples indicated a monoallelic expression (i.e., preferential expression of one allele). These results suggest that 1) the predominant allelic expression pattern of BCRP in placental samples is biallelic, and 2) the mutation C421A is not a genetic variant acting in cis, but is considered to influence the translation efficiency.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15475413     DOI: 10.1124/dmd.104.001628

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  74 in total

Review 1.  Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.

Authors:  Maarten J Deenen; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2011-05-31

2.  Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP.

Authors:  Hiroyuki Kusuhara; Hidetoshi Furuie; Akihiro Inano; Akihiro Sunagawa; Saiko Yamada; Chunyong Wu; Shinya Fukizawa; Nozomi Morimoto; Ichiro Ieiri; Mariko Morishita; Kiminobu Sumita; Hiroshi Mayahara; Takuya Fujita; Kazuya Maeda; Yuichi Sugiyama
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

Review 3.  Pharmacogenomics of the human ABC transporter ABCG2: from functional evaluation to drug molecular design.

Authors:  Toshihisa Ishikawa; Ai Tamura; Hikaru Saito; Kanako Wakabayashi; Hiroshi Nakagawa
Journal:  Naturwissenschaften       Date:  2005-10

Review 4.  ATP-binding cassette, subfamily G (ABCG family).

Authors:  Hiroyuki Kusuhara; Yuichi Sugiyama
Journal:  Pflugers Arch       Date:  2006-09-16       Impact factor: 3.657

5.  A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction.

Authors:  Yoshinori Shinohara; Naoto Takahashi; Kaichi Nishiwaki; Masayuki Hino; Makoto Kashimura; Hisashi Wakita; Yoshiaki Hatano; Akira Hirasawa; Yasuaki Nakagawa; Kuniaki Itoh; Hidekazu Masuoka; Nobuyuki Aotsuka; Yasuhiro Matsuura; Sinobu Takahara; Koji Sano; Jun Kuroki; Tomoko Hata; Hirohisa Nakamae; Atsuko Mugitani; Takahiko Nakane; Yasushi Miyazaki; Takenori Niioka; Masatomo Miura; Kenichi Sawada
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

6.  Sulfasalazine disposition in a subject with 376C>T (nonsense mutation) and 421C>A variants in the ABCG2 gene.

Authors:  Keisuke Gotanda; Tomoko Tokumoto; Takeshi Hirota; Masato Fukae; Ichiro Ieiri
Journal:  Br J Clin Pharmacol       Date:  2015-06-05       Impact factor: 4.335

7.  Personalised medicine in hypercholesterolaemia: the role of pharmacogenetics in statin therapy.

Authors:  Najmeh Ahangari; Mohammad Doosti; Majid Ghayour Mobarhan; Amirhossein Sahebkar; Gordon A Ferns; Alireza Pasdar
Journal:  Ann Med       Date:  2020-08-24       Impact factor: 4.709

Review 8.  Excretion of biliary compounds during intrauterine life.

Authors:  Rocio I R Macias; Jose J G Marin; Maria A Serrano
Journal:  World J Gastroenterol       Date:  2009-02-21       Impact factor: 5.742

9.  Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations.

Authors:  Tomoka Furukawa; Kanako Wakabayashi; Ai Tamura; Hiroshi Nakagawa; Yoshihiro Morishima; Yoichi Osawa; Toshihisa Ishikawa
Journal:  Pharm Res       Date:  2008-10-29       Impact factor: 4.200

10.  Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia.

Authors:  Luciene Terezina de Lima; Douglas Vivona; Carolina Tosin Bueno; Rosario D C Hirata; Mario H Hirata; André D Luchessi; Fabíola Attié de Castro; Maria de Lourdes F Chauffaille; Maria A Zanichelli; Carlos S Chiattone; Vania T M Hungria; Elvira M Guerra-Shinohara
Journal:  Med Oncol       Date:  2014-01-29       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.